- Home
- ABSI vs CLLS Comparison
ABSI vs CLLS Comparison
Compare ABSI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- CLLS
- Stock Information
- Founded
- ABSI 2011
- CLLS 1999
- Country
- ABSI United States
- CLLS France
- Employees
- ABSI N/A
- CLLS N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- CLLS Health Care
- Exchange
- ABSI Nasdaq
- CLLS Nasdaq
- Market Cap
- ABSI 338.0M
- CLLS 299.0M
- IPO Year
- ABSI 2021
- CLLS 2007
- Fundamental
- Price
- ABSI $2.62
- CLLS $2.99
- Analyst Decision
- ABSI Strong Buy
- CLLS Buy
- Analyst Count
- ABSI 5
- CLLS 1
- Target Price
- ABSI $7.98
- CLLS $4.00
- AVG Volume (30 Days)
- ABSI 4.1M
- CLLS 77.9K
- Earning Date
- ABSI 11-11-2025
- CLLS 11-03-2025
- Dividend Yield
- ABSI N/A
- CLLS N/A
- EPS Growth
- ABSI N/A
- CLLS N/A
- EPS
- ABSI N/A
- CLLS N/A
- Revenue
- ABSI $4,138,000.00
- CLLS $63,438,000.00
- Revenue This Year
- ABSI $44.71
- CLLS N/A
- Revenue Next Year
- ABSI $374.26
- CLLS $66.76
- P/E Ratio
- ABSI N/A
- CLLS N/A
- Revenue Growth
- ABSI 27.32
- CLLS 223.09
- 52 Week Low
- ABSI $2.01
- CLLS $1.10
- 52 Week High
- ABSI $6.33
- CLLS $3.35
- Technical
- Relative Strength Index (RSI)
- ABSI 49.98
- CLLS 61.44
- Support Level
- ABSI $2.37
- CLLS $2.88
- Resistance Level
- ABSI $2.89
- CLLS $3.35
- Average True Range (ATR)
- ABSI 0.15
- CLLS 0.17
- MACD
- ABSI 0.03
- CLLS 0.01
- Stochastic Oscillator
- ABSI 52.63
- CLLS 57.65
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.